Speculative High-Return Idea - LONG "TEVA"I'm not gonna explain the fundamental data of the company for a long time, but I will say briefly that if you look at the dynamics of changes in the company's data, you can see a stable growth of the EPS indicators and a gradual moving towards a positive P&L. It is also indicative that with the huge fall of markets last week, the company did not “fly down” after the market. In the pharmaceutical sector, which itself is risky for investors, TEVA in recent months has shown good growth and the POTENTIAL for the long-term trend to transition from falling to rising. It has already broken up the resistance line lasting from the highest 2015 year point. However, the idea of this post is no longer in long-term investment in this asset, but in speculative buying. The graph clearly shows the divergence of the asset price lows and its RSI and MACD indicators. According to Fibonacci, the stock adjusted to the desired level. Perhaps the fall to the level of 3703 Israeli Shekels and a rebound, or a rebound will be tomorrow. In any case, it is recommended to wait until the RSI fixes above 30 on the 1-hour chart, and then go into the idea. The way out of the idea is at least 4100 Shekels. Stop loss at your discretion, but 3650 is recommended. If you do not have access to the Israeli market, then do not be discouraged, paper is also listed in America under the same name TEVA P.S. It’s up to you to enter long-term or speculate, I recommend speculating only because I myself am a short-term speculator.Longby Eminence-Grise3
Cup and HandleThe chart depicts a classic cup and handle formation. Place a stop buy order slightly above the upper trend line of the handle. There is a risk of missing the trade if the price continues to advance and does not pull back. TEVA is still undervalued compared to fair value - they reported positive drug trial data in Japan, and had a nice breakout this week. gl!Longby IQimokucom6
TEVA Pharma breakout Teva Pharmaceutical Industries (NYSE:TEVA) Q4 results: Revenues:$4,468M (+1%); North America: $2,373M (+6%); Generics: $2,497M (+2%), Copaxone: $387M (-22%). Net income: $110M (+104%); non-GAAP net income: $683M (+26%); EPS: ($0.91); non-GAAP EPS: $0.10 (+104%). Consensus was non-GAAP EPS of $0.61 on revenues of $4.35B. Cash flow ops (full year): $748M (-69%). Decrease mainly due to the working capital adjustment with Allergan and the Rimsa settlement in 2018 and lower profits in North America in 2019. Cash flow ops in Q4: $538M (+47%). All components of 2019 outlook met, including spend base reduction target of $3B. 2020 guidance: Revenues: $16.6B - 17.0B; Copaxone sales: ~$1.2B; Austedo sales: ~$650M; AJOVY sales: ~$250M; non-GAAP EPS: $2.30 - 2.55; free cash flow: $1.8B - 2.2B. Source Seeking ALPHALongby RedHotStocks27
TEVA Accumulation Stronger than SPX NYSE:TEVA AMEX:SPY Teva - looks like Accumulation and starting to rise before Earnings next week Teva have Good Sentiment after new product that gave company reason to be optimistic small Entry and Adding last week Target with P&F looks for 17.5 - 18 for now will follow Have A great Week Longby eranajo227
TevaTeva Pharmaceuticals releases earnings in 6 days on February 11 2020. Potential Price Support-restance levels. The green box is the current difference maker for the upside, in which they it could aim to create a a 9 week: 13:10 and/or 10-week high 10:81 8 month high:15:44 :12 month: 15:91 The red line is the is still the long term support/resistance. 9.88by Kobebuyen6
TEVA - Break-Out of Cup and Handle formationTEVA Breaking out with heavy volume of a cup and handle formation. Target to fill gap of $14-$15.Longby The-Trend-is-the-Friend4
$TEVA long to $12, possible $15-$20Long $TEVA to at least $12 this week on technical basis alone. Could go for $15-$20 into March depending on earnings report on 2/12. DYOD - do your own due-diligence. Longby JtotheA119
Love this stock 13PT +Even in a down market this one holds and waits to jump up. See chart. Easy 13 in a month or 2.Longby TheAmericanTaxpayer4
Long Idea Weekly15/Jan/2020 06:38 PM AUTHOR: Brandon Gum -- Not sure on the target leading to the low RR. New RSI confirms the move. ======================Longby gumbtg5
Teva Pharma Bullish Golden CrossBeautiful recovery from the lows. Volume is increasing. Moving averages in Bullish formation. MACd and Histogram, Bullish. Longby Bullishcharts1161
TEVA BULLISH FLAGBuyer s have broken upper trend line on a Bullish flag pattern confirmed the entry which was backed by huge volume, Of we goLongby simtrader19a4
Great opportunity coming up Teva is going to hit a major resistance line causing a bounce back making two very high-profit scenarios that can be taken advantage of. I would recommend a entry of $8.50 or higher and an exit with your own judgment and stop losses.Longby AnirudL335
Daily inverted hammer bullish PT 13.5Love this stock for upside play, last daily candle formed a inverted hammer (Bullish) Great long term playLongby TheAmericanTaxpayer4
$TEVA - Following the Fibo and the triangularMA50 with positive gradient can be good for support. I wish the company stepping forward to a better direction in 2020. by Samuel12_19803
Broke golden cross / broke resistensGolden cross was made, broke strong resistens and closed over 9.45 ish ( closed over 10 ) RSI over 0,50 ( higher highs - higher lows ) bullish engulfing was made yesterday daily timeframe I opened a buy Open : 10,05 SL : 09,50 TP : 12,00 im new here and this is my 2 end post - please do say your opinion Longby SimpleinvestMarttinUpdated 7
Teva Pharma Bullish trade Entry level $10.34 = Target price $11.50 = Stop loss $10.00 Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines. The Generic Medicines segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment engages in the provision of core therapeutic areas of central nervous system medicines. The company was founded in 1901 and is headquartered in Petach Tikva, IsraelLongby Bullishcharts37
Long with caution, Holding long till gap fill 14 PTLong with caution, Holding long till gap fill 14 PTLongby TheAmericanTaxpayerUpdated 333